Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?

医学 血栓性微血管病 内科学 机会之窗 移植 微血管病 危险分层 分层(种子) 窗口(计算) 治疗窗口 重症监护医学 心脏病学 生物 工程类 糖尿病 计算机科学 疾病 内分泌学 航空航天工程 操作系统 发芽 药理学 种子休眠 植物 休眠
作者
Sonata Jodele,Christopher E. Dandoy,Anthony Sabulski,Jane Koo,Adam Lane,Kasiani C. Myers,Gregory Wallace,Ranjit S. Chima,Ashley Teusink‐Cross,Russel Hirsch,Thomas D. Ryan,Stefanie W. Benoit,Stella M. Davies
出处
期刊: [Elsevier BV]
卷期号:28 (7): 392.e1-392.e9 被引量:19
标识
DOI:10.1016/j.jtct.2022.04.019
摘要

Transplantation-associated thrombotic microangiopathy (TA-TMA) can range from a self-limiting condition to a lethal transplantation complication. It is important to identify TA-TMA patients at risk for severe multiorgan endothelial injury to implement targeted therapies in a timely manner. Current therapeutic approaches with complement blockade have improved survival markedly in high-risk TA-TMA patients, yet one-third of these patients respond inadequately to eculizumab therapy. Poor response may indicate that substantial endothelial injury has already occurred and raises the possibility that earlier intervention may improve outcomes. The goal of this study was to identify additional TA-TMA patients who would benefit from early targeted intervention and update TA-TMA risk stratification methods to reflect these findings. We studied 130 HSCT recipients with a diagnosis of TA-TMA who were screened prospectively and stratified into 3 TA-TMA risk groups (high-risk, n = 64; moderate-risk, n = 48; 18 low-risk, n = 18). We specifically examined TA-TMA biomarkers and clinical outcomes in subjects who were not offered complement blocking therapy (moderate-risk and low-risk TA-TMA subjects) and compared them with those who received TA-TMA-targeted therapy (high-risk TA-TMA subjects). One-year post-HSCT survival for subjects with untreated moderate-risk TA-TMA was similar to those with high-risk TA-TMA receiving eculizumab therapy (71% versus 66%; P = .40), indicating that a subset of moderate-risk patients may benefit from therapy. A detailed analysis of moderate-risk subjects highlighted the importance of relative as well as absolute complement pathway activation in determining organ injury. We demonstrated that activated terminal complement (measured by elevated blood sC5b-9) alone is a valuable indicator of reduced survival. Moderate-risk TA-TMA subjects with elevated sC5b-9 levels had a nearly 3-fold higher risk of mortality that was statistically significant in multivariant analyses (P = .01). A "dose effect" also was observed, and higher sC5b-9 levels were associated with worse outcomes. Furthermore, all moderate-risk patients with sustained sC5b-9 elevation for >2 weeks ultimately developed multiorgan dysfunction syndrome (MODS). This indicates that scheduled sC5b-9 measurements could promptly identify patients at risk for poor outcomes and would facilitate early TA-TMA-directed therapy to prevent organ injury. Untreated low-risk TA-TMA patients had a 1-year post-HSCT survival of 94% and should be observed without targeted interventions. Routine TA-TMA screening and complement-blocking therapies have markedly improved the outcomes for high-risk TA-TMA patients, and our study suggests that additional patients may benefit from TA-TMA treatment. This study provides further support for prospective TA-TMA screening as an integral tool for identifying patients at greatest risk for organ injury and death from TA-TMA. An updated TA-TMA risk algorithm that incorporates relevant laboratory biomarkers, clinical findings, and comorbid conditions was generated using this study's findings, and we propose clinical implementation of this algorithm for the management of TA-TMA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
上官若男的应助被zcm1314521采纳,获得10
刚刚
yy发布了新的文献求助10
1秒前
zww发布了新的文献求助10
2秒前
2秒前
zhangj完成签到 ,获得积分10
3秒前
4秒前
4秒前
4秒前
烟花的应助被DUMPLINGS采纳,获得10
5秒前
Kyle发布了新的文献求助10
6秒前
stuffmatter发布了新的文献求助100
6秒前
吃葡萄不吐葡萄皮的应助被PJ采纳,获得10
6秒前
6秒前
6秒前
left_right发布了新的文献求助10
6秒前
科研通AI6.2的应助被鳎mu采纳,获得10
6秒前
秋风的应助被kidult采纳,获得20
7秒前
科研巨头大J哥完成签到,获得积分10
7秒前
cwq关闭了cwq的文献求助
7秒前
AAA发布了新的文献求助20
8秒前
seal完成签到,获得积分10
8秒前
廷牧发布了新的文献求助10
8秒前
9秒前
美满惜雪发布了新的文献求助10
10秒前
10秒前
11秒前
pumpkin完成签到,获得积分10
11秒前
调皮万宝路完成签到,获得积分10
11秒前
领导范儿的应助被碧蓝梦寒采纳,获得10
12秒前
所所的应助被圆滚滚的大肥猫采纳,获得10
12秒前
12秒前
归宁发布了新的文献求助10
12秒前
重阳糕发布了新的文献求助10
12秒前
13秒前
领导范儿的应助被博纳清采纳,获得10
13秒前
lsy发布了新的文献求助30
14秒前
14秒前
机灵紫夏完成签到 ,获得积分10
15秒前
司空老五发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172327
求助须知:如何正确求助?哪些是违规求助? 9564990
关于积分的说明 21777687
捐赠科研通 7763968
什么是DOI,文献DOI怎么找? 3431223
关于科研通互助平台的介绍 2555098
邀请新用户注册赠送积分活动 2476246